Molecular Biometrics is a Norwood, MA–based metabolomics company developing clinical diagnostic tools for personalized medicine. Its proprietary technology is being applied in reproductive health, IVF and neurodegenerative disease (e.g., Parkinson’s disease). The company's flagship product is ViaMetrics-E, a non-invasive procedure designed to enhance in vitro fertilization (IVF) outcomes. Molecular Biometrics completed a $12.5M Series B equity financing to accelerate the global launch of ViaMetrics-E, implement manufacturing and product enhancements, and complete its ongoing FDA clinical study. The financing was led by Atlas Venture with participation from existing investors Safeguard Scientifics and Oxford Bioscience Partners. The company intends to use the proceeds to support commercialization and regulatory efforts for its IVF-focused diagnostic offering.

Total raised

$13M

Funding rounds

1

Latest round

Series B

Latest activity

Jan 2010